Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 3/8/24 A | Option | Chief Executive Officer | 35,000 | 0.0665% | ||
| 3/8/24 A | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 3/8/24 A | Option | Chief Technology Officer | 16,666 | 0.0317% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +0.93% | +6.97% | +62.83% | +67.97% | 56.67B | |
| -1.92% | +6.03% | +43.68% | +84.56% | 55.92B | |
| -0.46% | -1.29% | +3.28% | +422.58% | 23.28B | |
| -2.97% | -2.35% | -22.03% | -16.54% | 23.28B | |
| -0.36% | +5.73% | +30.99% | -3.58% | 20.54B | |
| -1.34% | +0.51% | +25.02% | -30.27% | 17.78B | |
| -1.44% | +5.67% | +32.54% | +544.11% | 15.9B | |
| -1.30% | -5.02% | +165.62% | +291.37% | 14.64B | |
| -0.50% | -0.98% | +23.62% | +178.38% | 13.99B | |
| Average | -0.94% | -0.01% | +40.62% | +170.95% | 26.89B | |
| Weighted average by Cap. | -0.89% | +1.19% | +41.00% | +135.67% |
Employees
11
